{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:39:08Z","timestamp":1794847148459,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10096-024-04932-6","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:20:01Z","timestamp":1726737601000},"page":"2453-2457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Understanding the rationale and clinical impact of the revised CLSI 2024 minocycline susceptibility breakpoints against Stenotrophomonas maltophilia"],"prefix":"10.1007","volume":"43","author":[{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvashri","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Gunasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Walia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"1","key":"4932_CR1","doi-asserted-by":"publisher","first-page":"ofaa008","DOI":"10.1093\/ofid\/ofaa008","volume":"7","author":"AM Hamdi","year":"2020","unstructured":"Hamdi AM, Fida M, Abu Saleh OM, Beam E (2020) Stenotrophomonas Bacteremia Antibiotic susceptibility and prognostic determinants: Mayo Clinic 10-Year experience. Open Forum Infect Dis 7(1):ofaa008","journal-title":"Open Forum Infect Dis"},{"issue":"31","key":"4932_CR2","doi-asserted-by":"publisher","first-page":"e4375","DOI":"10.1097\/MD.0000000000004375","volume":"95","author":"YD Jeon","year":"2016","unstructured":"Jeon YD, Jeong WY, Kim MH, Jung IY, Ahn MY, Ann HW et al (2016) Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Med (Baltim) 95(31):e4375","journal-title":"Med (Baltim)"},{"issue":"4","key":"4932_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14787210.2020.1730178","volume":"18","author":"T Gil-Gil","year":"2020","unstructured":"Gil-Gil T, Mart\u00ednez JL, Blanco P (2020) Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge. Expert Rev Anti Infect Ther 18(4):335\u2013347","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"4932_CR4","doi-asserted-by":"publisher","first-page":"e01558","DOI":"10.1128\/AAC.01558-19","volume":"63","author":"IH Chen","year":"2019","unstructured":"Chen IH, Kidd JM, Abdelraouf K, Nicolau DP (2019) Comparative in vivo antibacterial activity of human-simulated exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the murine thigh model. Antimicrob Agents Chemother 63(12):e01558\u2013e01519","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4932_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QCO.0000000000000975","volume":"36","author":"MF Mojica","year":"2023","unstructured":"Mojica MF, Bonomo RA, van Duin D (2023) Treatment approaches for severe Stenotrophomonas maltophilia infections. Curr Opin Infect Dis 36(6):572\u2013584","journal-title":"Curr Opin Infect Dis"},{"issue":"7","key":"4932_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00228-016-2043-z","volume":"272","author":"D Niedrig","year":"2016","unstructured":"Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S (2016) Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol 272(7):859\u2013867","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"4932_CR7","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/antibiotics12050910","volume":"12","author":"AE Maraolo","year":"2023","unstructured":"Maraolo AE, Licciardi F, Gentile I, Saracino A, Belati A, Bavaro DF (2023) Stenotrophomonas maltophilia infections: a systematic review and Meta-analysis of comparative efficacy of available treatments, with critical Assessment of Novel Therapeutic options. Antibiot (Basel) 12(5):910","journal-title":"Antibiot (Basel)"},{"issue":"2","key":"4932_CR8","doi-asserted-by":"publisher","first-page":"e01603","DOI":"10.1128\/JCM.01603-19","volume":"58","author":"M Biagi","year":"2020","unstructured":"Biagi M, Tan X, Wu T, Jurkovic M, Vialichka A, Meyer K et al (2020) Activity of potential alternative treatment agents for Stenotrophomonas maltophilia isolates Nonsusceptible to Levofloxacin and\/or trimethoprim-sulfamethoxazole. J Clin Microbiol 58(2):e01603\u2013e01619","journal-title":"J Clin Microbiol"},{"issue":"5","key":"4932_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","volume":"25","author":"JH Ko","year":"2019","unstructured":"Ko JH, Kang CI, Cornejo-Ju\u00e1rez P, Yeh KM, Wang CH, Cho SY et al (2019) Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect 25(5):546\u2013554","journal-title":"Clin Microbiol Infect"},{"key":"4932_CR10","first-page":"106002802312018","volume":"30","author":"EC Hevia","year":"2023","unstructured":"Hevia EC, Wooten L, Carr AL (2023) Trimethoprim\/Sulfamethoxazole vs Minocycline for the treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia infections in hospitalized patients. Ann Pharmacother 30:10600280231201850","journal-title":"Ann Pharmacother"},{"key":"4932_CR11","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.2147\/IDR.S416678","volume":"16","author":"P Boonmee","year":"2023","unstructured":"Boonmee P, Nasomsong W, Lorchirachoonkul N, Pungcharoenkijkul S, Juntanawiwat P, Chaemchaeng S, Santimaleeworagun W (2023) The activities of antimicrobials against Stenotrophomonas maltophilia isolates and evaluation of clinical outcomes among treatment regimens in patients with Stenotrophomonas maltophilia infections: a retrospective Multicenter Cohort Study. Infect Drug Resist 16:5173\u20135184","journal-title":"Infect Drug Resist"},{"issue":"2","key":"4932_CR12","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.ijantimicag.2021.106367","volume":"58","author":"SJ Junco","year":"2021","unstructured":"Junco SJ, Bowman MC, Turner RB (2021) Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim\/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents 58(2):106367","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4932_CR13","doi-asserted-by":"publisher","first-page":"dlad049","DOI":"10.1093\/jacamr\/dlad049","volume":"5","author":"SH Sarzynski","year":"2023","unstructured":"Sarzynski SH, Lawandi A, Warner S, Demirkale CY, Strich JR, Dekker JP et al (2023) Association between minimum inhibitory concentration values and mortality risk in patients with Stenotrophomonas maltophilia infections: a retrospective cohort study of electronic health records from 148 US hospitals. JAC Antimicrob Resist 5(2):dlad049","journal-title":"JAC Antimicrob Resist"},{"key":"4932_CR14","doi-asserted-by":"publisher","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","volume":"18","author":"PD Tamma","year":"2023","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2023) Infectious Diseases Society of America 2023 Guidance on the treatment of Antimicrobial resistant gram-negative infections. Clin Infect Dis 18:ciad428","journal-title":"Clin Infect Dis"},{"key":"4932_CR15","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2024) Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_14.0_Breakpoint_Tables.pdf"},{"key":"4932_CR16","unstructured":"Clinical and Laboratory Standards Institute (2024) Performance standards for antimicrobial testing. 34th ed, CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"4932_CR17","volume-title":"M-07-A10","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M-07-A10, 11th edn. Clinical and Laboratory Standards Institute, Wayne, PA","edition":"11"},{"issue":"3","key":"4932_CR18","doi-asserted-by":"publisher","first-page":"dlac040","DOI":"10.1093\/jacamr\/dlac040","volume":"4","author":"MF Mojica","year":"2022","unstructured":"Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, Fouts DE, Van Duin D, Bonomo RA (2022) Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist 4(3):dlac040","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"4932_CR19","doi-asserted-by":"publisher","first-page":"106878","DOI":"10.1016\/j.ijantimicag.2023.106878","volume":"62","author":"YL Lee","year":"2023","unstructured":"Lee YL, Liu CE, Ko WC, Hsueh PR (2023) In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004\u20132020. Int J Antimicrob Agents 62(2):106878","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"4932_CR20","doi-asserted-by":"publisher","first-page":"e0109421","DOI":"10.1128\/JCM.01094-21","volume":"59","author":"DD Rhoads","year":"2021","unstructured":"Rhoads DD (2021) Stenotrophomonas maltophilia Susceptibility Testing challenges and strategies. J Clin Microbiol 59(9):e0109421","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4932_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/jac\/dkab344","volume":"77","author":"AJ Fratoni","year":"2021","unstructured":"Fratoni AJ, Nicolau DP, Kuti JL (2021) Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. J Antimicrob Chemother 77(1):164\u2013168","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4932_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/jac\/dkac018","volume":"77","author":"AJ Fratoni","year":"2022","unstructured":"Fratoni AJ, Nicolau DP, Kuti JL (2022) Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. J Antimicrob Chemother 77(4):1052\u20131060","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4932_CR23","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1093\/jac\/dkw327","volume":"71","author":"S Jacobson","year":"2016","unstructured":"Jacobson S, Junco Noa L, Wallace MR, Bowman MC (2016) Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother 71(12):3620","journal-title":"J Antimicrob Chemother"},{"key":"4932_CR24","first-page":"e02387","volume":"4","author":"K Rolston","year":"2020","unstructured":"Rolston K, Gerges B, Shelburne S, Aitken S, Raad I, Prince R (2020) Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother 4:e02387\u2013e02319","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4932_CR25","doi-asserted-by":"publisher","first-page":"e0065421","DOI":"10.1128\/JCM.00654-21","volume":"59","author":"A Khan","year":"2021","unstructured":"Khan A, Arias CA, Abbott A, Dien Bard J, Bhatti MM, Humphries RM (2021) Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial susceptibility testing of Stenotrophomonas maltophilia. J Clin Microbiol 59(9):e0065421","journal-title":"J Clin Microbiol"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04932-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04932-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:12:33Z","timestamp":1732986753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04932-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4932"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04932-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"statement: Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}